Investor Relations

Investor Relations

Corporate Profile

Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders. We commercialize a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the core sleep, cardiology and direct to consumer markets.

Our prescription WatchPAT family of products, which utilizes the PAT signal, is designed to enable patients suspected to have sleep related breathing disorders to easily conduct sleep apnea tests in the comfort of their homes in accordance with a physician’s instructions, as authorized by qualified medical personnel while delivering the treating physicians with comprehensive, accurate and reliable results to aid in the diagnosis of sleep apnea.

 
Stock Information
Press Releases
Oct
2020
Itamar Medical Announces Appointment of Shane Brown as President – U.S.
Oct
2020
Itamar™ Medical Announces Third Quarter Preliminary Revenue Results and Reinstates Revenue Guidance for Full Year 2020
Oct
2020
Itamar Medical Wins National Sleep Foundation 2020 SleepTech® Award
Oct
2020
Itamar Medical’s WatchPAT™300 Home Sleep Apnea Testing Device Receives Approval in Japan
Sep
2020
The German Sleep Society (DGSM) Recognizes PAT™ based Technology in its New Sleep-Related Breathing Disorders Guidelines, Further Benefitting Itamar Medical’s Approach to Sleep Apnea Diagnosis
Sep
2020
Itamar Medical to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020
Investor Events
Sep
2020
H.C. Wainwright 22nd Annual Global Investment Conference
Aug
2020
Notice of annual shareholders meeting
Aug
2020
Q2 2020 Itamar Medical Ltd. Earnings Conference Call
Jun
2020
Virtual Fireside Chat with Piper Sandler & Co.
Investor Presentations
Management